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Interventional Cardiology
Clinical Benefit of Statin Pretreatment in Patients
Undergoing Percutaneous Coronary Intervention
A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies
Giuseppe Patti, MD; Christopher P. Cannon, MD; Sabina A. Murphy, MPH; Simona Mega, MD;
Vincenzo Pasceri, MD, PhD; Carlo Briguori, MD, PhD; Antonio Colombo, MD; Kyeong Ho Yun, MD;
Myung Ho Jeong, MD, PhD; Jung-Sun Kim, MD; Donghoon Choi, MD; Huseyin Bozbas, MD;
Masayoshi Kinoshita, MD; Keiichi Fukuda, MD, PhD; Xin-Wei Jia, MD; Hidehiko Hara, MD;
Serkan Cay, MD; Germano Di Sciascio, MD
Background—Previous studies suggested that statin pretreatment reduces cardiac events in patients undergoing
percutaneous coronary intervention. However, most data were observational, and single randomized trials included
limited numbers of patients.
Methods and Results—We performed a collaborative meta-analysis using individual patient data from 13 randomized
studies in which 3341 patients received either high-dose statin (n1692) or no statin/low-dose statin (n1649) before
percutaneous coronary intervention, with all patients receiving statin therapy after intervention. Occurrence of
periprocedural myocardial infarction, defined as postintervention creatine kinase–MB increase 3 times the upper limit
of normal, and 30-day major adverse cardiac events (death, myocardial infarction, target-vessel revascularization) was
evaluated. Incidence of periprocedural myocardial infarction was 7.0% in the high-dose statin versus 11.9% in the
control group, which corresponds to a 44% risk reduction in the active-treatment arm (odds ratio by fixed-effects model
0.56, 95% confidence interval, 0.44 to 0.71, P0.00001). The rate of major adverse cardiac events at 30 days was
significantly lower in the high-dose statin group (7.4% versus 12.6%, a 44% risk reduction; P0.00001), and 1-month
major adverse cardiac events, excluding periprocedural events, were also reduced (0.6% versus 1.4%; P0.05). The
benefit of high-dose statins was realized irrespective of clinical presentation (P for interaction0.43) and was
maintained across various subgroups but appeared greater in the subgroup with elevated baseline C-reactive protein
levels (n734; 68% risk reduction for periprocedural myocardial infarction versus 31% in those 1861 patients with
normal CRP; P for quantitative interaction0.025).
Conclusions—High-dose statin pretreatment leads to a significant reduction in periprocedural myocardial infarction and
30-day adverse events in patients undergoing percutaneous coronary intervention. This strategy should be considered in
all patients with planned percutaneous coronary intervention. (Circulation. 2011;123:1622-1632.)
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Percutaneous coronary intervention (PCI) represents theprevalent revascularization strategy in patients with cor-
onary artery disease. Although this procedure is safe and is
associated with low rates of severe complications, periproce-
dural myocardial infarction, as assessed by cardiac marker
elevation, occurs in 5% to 40% of patients, depending on the
definition applied, antithrombotic approaches, and clinical/
angiographic risk profile,1–4 and it is well known that this
complication may negatively impact clinical outcome after
intervention.2,3,5 Thus, various strategies, usually focused on
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improvement of antithrombotic therapy, have been evaluated
to decrease the incidence of cardiac ischemic events during
PCI (use of glycoprotein IIb/IIIa antagonists, -blockers,
optimization of clopidogrel loading, and new antiplatelet
agents).6–10
Clinical Perspective on p 1632
In the last few years, experimental studies demonstrated
that statins have cardioprotective effects in the animal model
of ischemia/reperfusion,11,12 and clinical data indicated that
pretreatment with statins may significantly reduce periproce-
dural complications and major adverse cardiac events
(MACE) in patients undergoing PCI13–15; however, those data
mainly derive from observational studies, whereas single
randomized trials on this topic included a limited number of
patients and were not powered to evaluate post-PCI
events.16–28 It may be difficult to reach definitive conclusions
on the basis of the results of individual studies; thus, we
performed a collaborative patient-level meta-analysis of ran-
domized, controlled trials that evaluated the clinical benefit of
statin pretreatment in the setting of PCI to quantify the effect
of such therapy on the reduction of periprocedural myocardial
infarction and MACE at 30 days.
Methods
Data Sources and Selection Criteria
The MEDLINE and PubMed databases (from 1996 to 2010) were
searched, and cited references were reviewed to identify prospective
randomized trials that compared the clinical outcome of high-dose
versus no statin or low-dose statin pretreatment in patients undergo-
ing PCI. Search keywords were “statins,” “statin,” “atorvastatin,”
“rosuvastatin,” “cerivastatin,” “simvastatin,” “pravastatin,” “lova-
statin,” and “hydroxymethylglutaryl-CoA,” combined with the
words “angioplasty,” “stent,” “coronary,” and “randomized.” No
restriction on subheadings was applied. Presentations at major
cardiology congresses (meetings of the European Society of Cardi-
ology, American College of Cardiology, and American Heart Asso-
ciation) were checked through meetings proceedings, official Web
sites, and direct attendance at the meetings. All references of relevant
trials were also reviewed.
Data Collection
We included 13 clinical trials; full descriptions of the study designs,
sample characteristics, treatment protocols, and outcome findings
have been reported elsewhere.16–28 No identified studies were
excluded. Principal investigators of each of the 13 trials were invited
to send the requested patient-level data regarding main clinical and
procedural features in the study population, as well as individual
outcome data, including levels of creatine kinase–MB (CK-MB) and
troponin before and after intervention; periprocedural high-
sensitivity C-reactive protein (CRP) levels; and occurrence of death,
stent thrombosis, unplanned target-vessel revascularization, myocar-
dial infarction up to 30 days, or relevant drug-related side effects. Of
the 13 studies, 12 agreed to participate in the patient-level analysis
and 1 declined.22 An electronic form that contained those data fields
to be completed for individual patients was sent to the principal
investigators who agreed to participate. All data were verified
thoroughly for consistency (logical checking and checking
against the original publications). Any disagreements were re-
solved, and final database entries were verified by the responsible
trial investigator.
Quality of the Studies
Studies were evaluated for the adequacy of allocation concealment
and performance of the analysis according to the intention-to-treat
principle. Criteria previously described by Altman and Schulz29 were
used to determine adequate concealment of the treatment allocation.
We did not perform weighting of the studies by quality scores
because this practice has been discouraged previously in controlled
clinical trials.30
End-Point Definitions
Individual data were pooled for comparison of the incidence of
periprocedural myocardial infarction and MACE at 30 days in the 2
arms (high-dose statin pretreatment versus control). The control
group included patients who received either no statin or low-dose
statin before PCI.
For the purpose of this meta-analysis, to allow optimal compara-
bility, a standard definition of periprocedural infarction was applied
for all studies according to the universal definition,31 even if the
study used a different definition of periprocedural myocardial
infarction: In patients with stable angina or non–ST-segment eleva-
tion acute coronary syndrome (ACS), periprocedural infarction was
defined as a postintervention CK-MB increase 3 times the upper
limit of normal (ULN), whereas in patients with ST-segment
elevation myocardial infarction, it was defined as a 20% increase
from the baseline value in CK-MB or troponin levels in the second
sample drawn after 3 to 6 hours. A secondary analysis of peripro-
cedural myocardial injury was defined as any postintervention
elevation of troponin levels1ULN. Other exploratory definitions
of periprocedural myocardial ischemic events included post-PCI
CK-MB raise 1ULN and troponin elevation 3ULN. We also
report data according to the “per trial” definition of periprocedural
myocardial infarction.
The composite end point of the analysis was incidence of MACE,
defined as death, myocardial infarction, or target-vessel revascular-
ization, by 30 days. Other MACE end points were evaluated for
consistency, including death, myocardial infarction, target-vessel
revascularization, or stent thrombosis by 30 days, as well as both
MACE end points using only spontaneous myocardial infarction
rather than both spontaneous infarction and periprocedural infarc-
tion. The components of the MACE end points were also evaluated
individually.
Outcome data were available through 30 days for all patients of
the included studies, except those by Bozbas et al,24 Jia et al,26 and
Cay et al,28 which collected data only on in-hospital events. In
addition, the study by Veselka et al,22 who did not participate in the
patient-level meta-analysis, did not evaluate the 30-day clinical
outcome. For those 4 studies, which comprised 820 patients, in-
hospital events were used for the MACE end point. Periprocedural
high-sensitivity CRP level variation (postintervention CRP minus
baseline CRP) was evaluated in the 2 groups when those data were
available, as was the incidence of periprocedural infarction accord-
ing to baseline CRP levels.
Statistical Analysis
A patient-level pooled analysis was performed to evaluate the effect
of pretreatment with high-dose statin on outcome measures. The
analysis was performed according to the intention-to-treat strategy.
Percentages are presented for discrete variables and meanSD or
median (with 25th and 75th percentiles) for continuous variables.
Continuous variables were compared with the Wilcoxon rank sum
test. Differences between randomized groups for categorical vari-
ables were compared with a 2 test or Fisher exact test, as
appropriate. Treatment effects were estimated from logistic regres-
sion models and reported as odds ratio (OR) with 95% confidence
intervals (CIs). Subgroup analysis was performed in subjects by
index event of stable angina versus ACS and by use of glycoprotein
IIb/IIIa inhibitors, as well as according to other features (age, sex,
diabetes mellitus versus no diabetes, single-vessel versus multivessel
intervention, and presence or absence of elevated CRP).
To evaluate the robustness of the findings and the impact of the 1
study that declined to participate in the patient-level analysis, we
conducted a trial-level meta-analysis using the event rates in the
high-dose statin and control arms for each trial. The meta-analysis
was performed of the relative odds based on fixed-effects models. A
Patti et al High-Dose Statin Pretreatment in PCI 1623
test of heterogeneity, which evaluates variability in the treatment
effects, was performed by the Mantel-Haenszel method. The possi-
bility of publication bias was assessed by funnel plot analysis.32 A
2-sided P0.05 was considered statistically significant. With the
exception of the trial-level meta-analysis, all other statistical analy-
ses were performed with Stata/SE, version 9.2 (StataCorp, College
Station, TX). The trial-level meta-analysis was performed with
Review Manager 4.2.10 software (available from The Cochrane
Collaboration at http//www.cochrane.org). Thirty-day cardiac event
analysis was performed by the Kaplan-Meier method with log-rank
test group comparison.
Results
Main Features of Included Studies
Data from the aforementioned 13 prospective randomized
trials16 –28 that evaluated the effects of high-dose statin
pretreatment on clinical outcome in patients undergoing
PCI were analyzed (Table 1); 3341 patients were included
in the analysis, 1692 of whom were randomized to high-
dose statin and 1649 to low-dose or no statin therapy
(control group).
The clinical presentation of the patients included in the
studies and the drug assignment before PCI are indicated in
Table 1. Patients with severe renal failure or with liver or
muscle diseases were excluded. All studies except 2
(ARMYDA-RECAPTURE [Atorvastatin for Reduction of
Myocardial Damage During Angioplasty Recapture Trial]20
and the study by Hara et al27) included statin-naive patients.
In all studies, patients received statin therapy after the
intervention irrespective of the initial randomization assign-
ment (Table 1).
The pre-PCI bolus of unfractionated heparin was similar:
5000 IU in the studies by Yun et al19 and Jia et al,26 50 to 80
IU/kg in the study by Veselka et al,22 70 to 100 IU/kg in the
studies by Bozbas et al24 and Cay et al,28 100 IU/kg in the
study by Hara et al,27 and 70 IU/kg in the 3 ARMYDA
trials,16,18,20 the 2 studies by Briguori et al,17,21 and the study
by Kinoshita et al.25 In STATIN STEMI (Efficacy of High-
Dose Atorvastatin Loading Before Primary Percutaneous
Coronary Intervention in ST-Elevation Myocardial Infarc-
tion),23 weight-adjusted unfractionated heparin was given to
achieve a target activated clotting time of 300 seconds in
the absence of glycoprotein IIb/IIIa inhibitors and 200 to 300
seconds with glycoprotein IIb/IIIa inhibitors. Bivalirudin was
used instead of unfractionated heparin in 10% of patients in
ARMYDA-RECAPTURE20 and enoxaparin in 37% of those
in the study by Yun et al.19 Patients in all studies were
pretreated with aspirin; the ARMYDA trials and STATIN
STEMI16,18,20,23 used 600 mg of clopidogrel as a loading dose,
5 studies19,21,22,24,28 used a 300-mg loading dose, 3 stud-
ies17,25,26 used either ticlopidine or clopidogrel (75 mg/d)
starting 3 days before PCI, and ticlopidine or cilostazol was
given in the study by Hara et al.27 Glycoprotein IIb/IIIa
inhibitors were not used in 4 studies,22,24,25,27 whereas such
agents were administered, at the discretion of the operator, in
the following proportions of patients in the other studies: 52%
in the studies by Briguori et al,17 24% in ARMYDA-ACS,18
20% in ARMYDA16 and in the study by Jia et al,26 14% in
NAPLES (Novel Approaches for Preventing or Limiting
Events) II21 and in the study by Cay et al,28 12% in
ARMYDA-RECAPTURE,20 7% in the study by Yun et al,19
and 22% in STATIN STEMI.23 There were no differences in
periprocedural antithrombotic therapies between high-dose
statin pretreatment and control groups in any of the studies.
Main demographic, clinical, and procedural features in the
overall population are reported in Table 2. The prevalence of
patients with age 65 years was approximately 50%; 39% of
patients had ACS, and 28% had diabetes mellitus.
Periprocedural Outcome
Patient-level analysis demonstrated that overall, periproce-
dural myocardial infarction occurred in 6.8% of patients in
the high-dose statin pretreatment group versus 11.9% of those
in the control group, which corresponds to a 46% relative
reduction in the active-treatment arm (OR, 0.54, 95% CI, 0.42
to 0.70; P0.00001). When data from the study by Veselka
et al22 were added in a trial-level analysis, the findings for
periprocedural myocardial infarction were consistent: 7.0%
versus 11.9%, a 44% relative risk reduction (OR, 0.56, 95%
CI, 0.44 to 0.71; P0.00001; Table 3; Figure 1). There was
no evidence of significant heterogeneity among the 13 trials
(P0.62, I20%), and funnel plot analysis did not suggest
the presence of publication bias (Figure 1). High-dose statin
pretreatment was also associated with a significantly lower
incidence of periprocedural myocardial infarction per trial
definition (6.8% versus 15.1% in the control arm; OR, 0.40,
95% CI, 0.32 to 0.51; P0.00001).
Moreover, after high-dose statin pretreatment, there was a
decreased incidence of periprocedural myocardial injury (de-
fined as any post-PCI elevation of troponin levels above the
ULN): 34.9% versus 47.7% in the control group (OR, 0.59, 95%
CI, 0.51 to 0.68; P0.00001). When data from the study by
Veselka et al22 were added in a trial-level analysis, the findings
for periprocedural myocardial injury were consistent: 35.8%
versus 47.9% (OR, 0.57, 95% CI, 0.49 to 0.67; P0.00001;
Table 3). Results according to other exploratory definitions of
periprocedural myocardial ischemic events are indicated in
Table 3. Maximum CK-MB/ULN ratio and maximum troponin/
ULN ratio after PCI were also significantly lower in the
high-dose statin group (CK-MB: median 0.7 ng/mL, interquar-
tile range 0.4 to 1.1 ng/mL versus 0.8 ng/mL, interquartile range
0.5 to 1.6 ng/mL [P0.00001]; troponin: median 0.4 ng/mL,
interquartile range 0.1 to 1.8 ng/mL versus 0.8 ng/mL, interquar-
tile range 0.2 to 3.8 ng/mL [P0.00001]).
Adverse Events at 30 Days
The proportion of patients with MACE (including peripro-
cedural myocardial infarction) at 30 days was lower in the
high-dose statin pretreatment group (7.4% versus 12.6%;
OR, 0.56, 95% CI, 0.44 to 0.71; P0.00001; Table 3;
Figure 2); this outcome was mainly driven by periproce-
dural events in either arm (Figure 3). There was no
evidence of significant heterogeneity among the trials with
regard to outcome data through 1 month (P0.54, I20%;
Figure 2). However, when only spontaneous myocardial
infarctions (ie, not periprocedural infarctions) were
counted, rates of MACE were 0.6% in the high-dose statin
group versus 1.4% in the control arm, with an OR of 0.44
(95% CI, 0.19 to 1.01; P0.05), consistent with the overall
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result shown for MACE that included periprocedural
myocardial infarction (Table 3). Complete outcome data at
30 days are reported in Table 3; in particular, 30-day
mortality was 0.24% in the high-dose statin group versus
0.56% in the control group (OR, 0.42, 95% CI, 0.11 to
1.64; P0.20), and target-vessel revascularization oc-
curred in 0.32% versus 0.80% (OR, 0.39, 95% CI, 0.12 to
1.26; P0.10). No significant side effects (aspartate
transaminase/alanine transaminase or CK elevation 3
ULN) were associated with statin pretreatment in any
study.
CRP Data
High-sensitivity CRP levels were measured in 9 studies.16–21,24,26,27
Periprocedural CRP-level variation (postintervention CRP
minus baseline CRP) was lower in patients who received
Table 1. Main Descriptors of the 13 Trials Included
Trials
Patients,
n
Type of
Population Clinical Presentation
Type of
Statin
Statin Regimen Before
PCI
Statin Regimen
After PCI* Follow-Up
ARMYDA16 153 Statin naive Stable angina Atorvastatin 7-Day pretreatment
with 40 mg/d vs
placebo
Atorvastatin
40 mg/d
30 d
ARMYDA-ACS18 171 Statin naive NSTE-ACS Atorvastatin 80 mg 12 h before
PCI40 mg 2 h before
PCI vs placebo
Atorvastatin
40 mg/d
30 d
ARMYDA-RECAPTURE20 383 Statin-
treated
53% Stable angina;
47% NSTE-ACS
Atorvastatin 80 mg 12 h before
PCI40 mg 2 h before
PCI vs placebo
Atorvastatin
40 mg/d
30 d
Briguori et al17 451 Statin naive 92% Stable
angina/asymptomatic;
8% unstable angina
39%
Simvastatin;
29%
atorvastatin;
29%
pravastatin;
3%
fluvastatin
3-Day pretreatment
(average 17 days) vs no
statin pretreatment
The same statin
as before PCI in
the statin group
and atorvastatin
20 mg/d in the
control group
30 d
NAPLES II21 668 Statin naive 98% Stable
angina/asymptomatic;
2% unstable angina
Atorvastatin 80 mg24 h before
PCI vs no-statin
pretreatment
Atorvastatin
20 mg/d
30 d
STATIN STEMI23 171 Statin naive STEMI Atorvastatin 80 mg in the
emergency room vs 10
mg
Atorvastatin
10 mg/d
30 d
Veselka et al22 200 Statin naive Stable angina Atorvastatin 2-Day pretreatment
with 80 mg/d vs no
statin pretreatment
NA In-hospital
Yun et al19 445 Statin naive NSTE-ACS Rosuvastatin 40 mg 16 h before PCI
vs no statin
pretreatment
Rosuvastatin
10 to 40 mg/d
30 d
Bozbas et al24 93 Statin naive Stable angina Pravastatin 7-Day pretreatment
with 10 mg/d vs 40
mg/d vs no statin
pretreatment
Pravastatin
10 to 40 mg/d
In-hospital
Kinoshita et al25 42 Statin naive Stable angina Atorvastatin 5-20 mg/d2 wk
before PCI to reach
LDL-C70 vs100
mg/dL
A to rvastatin
5 to 20 mg/d
6 mo
Jia et al26 228 Statin naive 29% STEMI; 71%
NSTE-ACS
Simvastatin 7-Day pretreatment
with 80 mg vs 20 mg
Simvastatin
20 mg/d
In-hospital
Hara et al27 37 Statin naive
or statin
treated
NSTE-ACS Atorvastatin 20 mg 24 h before PCI
vs no statin
pretreatment
Atorvastatin
20 mg/d
30 d
Cay et al28 299 Statin naive Stable angina Rosuvastatin 40 mg 24 h before PCI
vs no statin
pretreatment
Rosuvastatin
10 to 40 mg/d
In-hospital
PCI indicates percutaneous coronary intervention; ARMYDA, Atorvastatin for Reduction of Myocardial Damage During Angioplasty; ARMYDA-ACS, ARMYDA–Acute
Coronary Syndrome; NSTE-ACS, non–ST-segment elevation acute coronary syndrome; ARMYDA-RECAPTURE, ARMYDA Recapture Trial; NAPLES II, Novel Approaches
for Preventing or Limiting Events II; STATIN STEMI, Efficacy of High-Dose Atorvastatin Loading Before Primary Percutaneous Coronary Intervention in ST-Elevation
Myocardial Infarction; STEMI, ST-segment elevation myocardial infarction; NA, not available; and LDL-C, low-density lipoprotein cholesterol.
*All patients received statin therapy after the intervention, irrespective of the initial randomization assignment.
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high-dose statin pretreatment: mean 3.410.0 mg/L, median
1.2 mg/L (interquartile range 0.0 to 4.9 mg/L) versus
5.616.2 mg/L, median 2.2 mg/L (interquartile range 0.4 to
5.8 mg/L; P0.00001).
In the subgroup of 1861 patients with normal baseline CRP
levels (by trial definition), incidence of periprocedural myo-
cardial infarction was 7.8% in the high-dose statin group
versus 10.9% in the control group, whereas in those 734
patients with elevated CRP levels, it was 4.3% versus 12.3%,
respectively (Figure 4); the OR for periprocedural myocardial
infarction in favor of high-dose statin pretreatment was 0.69
(95% CI, 0.50 to 0.95; P0.021) in patients with normal CRP
levels and 0.32 (95% CI, 0.18 to 0.58; P0.001) in those with
elevated CRP levels (P for quantitative interaction0.025, ie,
both analyses were in the same direction in favor of high-dose
statins, but the effect was greater in the subgroup with
elevated CRP).
Outcome According to Various Clinical Features
We pooled data to evaluate the grade of benefit provided by
high-dose statin pretreatment according to clinical presenta-
tion on admission (Figure 5). In the subgroup with stable
angina (n2293), high-dose statin pretreatment was associ-
ated with a lower incidence of periprocedural myocardial
infarction (7.5% in the high-dose statin group versus 13.2%
in the control group, which corresponds to a 48% relative risk
reduction [OR, 0.52, 95% CI, 0.41 to 0.66; P0.00001]). In
patients presenting with ACS (n1032), periprocedural myo-
cardial infarction occurred in 5.9% of patients in the high-
dose statin group and 9.0% of those in the control group (OR,
0.64; 95% CI, 0.40 to 1.02; P0.06). The interaction test for
clinical presentation was not significant (P0.43).
The ORs for periprocedural myocardial infarction in favor
of high-dose statin pretreatment were 0.71 (95% CI, 0.45 to
1.12; P0.16) in patients receiving glycoprotein IIb/IIIa
inhibitors (n603) and 0.49 (95% CI, 0.36 to 0.66;
P0.00001) in those not receiving these agents (n2519; P
for interaction0.18). Patient-level analysis demonstrated
that periprocedural myocardial protection by high-dose statin
Table 2. Clinical and Procedural Features in the Overall
Population (13 Trials; N3341)
Characteristics
High-Dose Statin
Pretreatment (n1692)
Controls
(n1649)
Age 65 y* 781 (49) 803 (52)
Men 1185 (70) 1231 (75)
Diabetes mellitus 502 (30) 444 (27)
Hypercholesterolemia 699 (41) 606 (37)
Systemic hypertension 1100 (65) 1083 (66)
Active smoker 452 (27) 343 (27)
Previous myocardial infarction 446 (26) 359 (22)
Clinical presentation
Chronic stable angina 1046 (62) 1009 (61)
ACS 646 (38) 640 (39)
Medical therapy
-blockers 904 (53) 857 (52)
ACE inhibitors/sartans 1081 (64) 1033 (631)
Multivessel disease 684 (40) 628 (38)
Multivessel PCI 317 (19) 264 (16)
Treated vessel
Left main 9 (1) 25 (1.5)
Left anterior descending 887 (52) 884 (54)
Left circumflex 452 (27) 444 (27)
Right coronary 493 (29) 474 (29)
Saphenous vein graft 10 (1) 9 (1)
Lesions B2/C 954 (56) 938 (57)
Antithrombotic therapy
Unfractionated heparin 1598 (95) 1539 (94)
Bivalirudin 19 (1) 21 (1)
Enoxaparin 75 (4) 89 (5)
Glycoprotein IIb/IIIa inhibitors 296 (17) 306 (19)
ACS indicates acute coronary syndrome (non–ST-segment elevation ACS or
ST-segment elevation myocardial infarction); ACE, angiotensin-converting
enzyme; and PCI, percutaneous coronary intervention.
Values are reported as n (%).
*Patients enrolled in the study by Veselka et al22 were excluded.
Table 3. Periprocedural and 30-Day Outcome Data in the 2 Groups
All Trials Pooled High-Dose Statin Pretreatment* Controls* OR (95% CI) P
Periprocedural MI 118 (7.0) 195 (11.9) 0.56 (0.44–0.71) 0.00001
Periprocedural myocardial injury defined as troponin post-PCI 1ULN) 572 (35.8) 746 (47.9) 0.57 (0.49–0.67) 0.00001
Other exploratory definitions of periprocedural myocardial ischemic events
Post-PCI CK-MB 1ULN 380 (25.4) 522 (35.9) 0.61 (0.52–0.71) 0.00001
Post-PCI troponin 3ULN 289 (19.3) 428 (29.4) 0.57 (0.48–0.68) 0.00001
Events at 30 days
Death 3 (0.24) 7 (0.56) 0.42 (0.11–1.64) 0.20
Spontaneous MI 3 (0.24) 2 (0.16) 1.49 (0.25–8.92) 0.66
TVR 4 (0.32) 10 (0.80) 0.39 (0.12–1.26) 0.10
ST 6 (0.47) 5 (0.40) 1.19 (0.36–3.91) 0.77
MACE (death/all MI/TVR) 125 (7.4) 208 (12.6) 0.56 (0.44–0.71) 0.00001
MACE (death/all MI/TVR/ST) 126 (7.5) 209 (12.7) 0.56 (0.44–0.71) 0.00001
MACE (death/spontaneous MI/TVR) 8 (0.6) 18 (1.4) 0.44 (0.19–1.01) 0.05
OR indicates odds ratio; CI, confidence interval; MI, myocardial infarction; PCI, percutaneous coronary intervention; ULN, upper limit of normal; CK-MB, creatine
kinase-MB; TVR, target-vessel revascularization; ST, stent thrombosis; and MACE, major adverse cardiac events.
*Reported as n (%).
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pretreatment was maintained across other subgroups of pa-
tients (Figure 5).
Discussion
This collaborative patient-level meta-analysis shows that
pretreatment with high-dose statins significantly reduces the
risk of adverse cardiac events and periprocedural myocardial
infarction in patients undergoing PCI. The finding was robust
across all the trials, and was present both in patients who were
undergoing PCI after ACS and in those with stable angina. In
addition, the benefit was observed in patients receiving
dual-antiplatelet therapy (aspirin and a thienopyridine) and in
those receiving triple-antiplatelet therapy (also receiving
glycoprotein IIb/IIIa inhibitors). High-dose statin therapy
reduced high-sensitivity CRP levels over the 24-hour period
immediately after PCI, which suggests that the antiinflamma-
tory effect of statins may be a mechanism by which such
therapy decreases periprocedural events.
Previous studies have shown that statin therapy, when
initiated early after the procedure, improves clinical outcome
in patients undergoing PCI.33 Moreover, data have suggested
that patients taking statins at the time of PCI have a lower
incidence of periprocedural cardiac ischemic events than
those who are statin naive13–15; however, those studies were
observational and nonrandomized, and included patients with
various risk profiles treated with different statins at variable
doses and with variable duration of therapy. This is critical,
and thus, the meaning of such observational data is question-
able and must be considered hypothesis generating. In the last
few years, prospective randomized studies have evaluated the
issue of whether a statin pretreatment, with fixed doses of a
specific agent for a short, definite period, may provide
periprocedural cardioprotection in the setting of PCI; the
majority of such studies demonstrated a benefit,16–21,23,25–28
but they did not include large numbers of patients, and 2
studies were not confirmatory.22,24 Therefore, only pooled
analyses that include a large patient population may help to
achieve definitive results; a meta-analysis34 was initially
performed on this issue, but it had relevant limitations
because it included only 2 prospective trials, which were
added into the same analysis as retrospective studies. Three
other meta-analyses35–37 have been published recently that
demonstrated the effectiveness of a statin pretreatment in the
setting of PCI, but those investigations did not include the
newest randomized studies, were conducted at a study level,
did not perform time-to-event and subgroup analyses, did not
evaluate occurrence of combined and individual MACE, and
considered the incidence of periprocedural myocardial infarc-
Figure 1. Top, Odds ratios (with 95% confidence interval) of periprocedural myocardial infarction in patients receiving high-dose statin pre-
treatment vs controls. Bottom, Funnel plot showing no evidence of publication bias. OR indicates odds ratio; CI, confidence interval;
ARMYDA, Atorvastatin for Reduction of Myocardial Damage During Angioplasty; ARMYDA-ACS, Atorvastatin for Reduction of Myocardial
Damage During Angioplasty–Acute Coronary Syndrome; ARMYDA-RECAPTURE, Atorvastatin for Reduction of Myocardial Damage During
Angioplasty–Acute Coronary Syndromes RECAPTURE; NAPLES II, Novel Approaches for Preventing or Limiting Events II; and STATIN
STEMI, Efficacy of High-Dose Atorvastatin Loading Before Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction.
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tion only according to the per trial definition. The present
meta-analysis, which included 3341 patients and was per-
formed at a patient level by a fixed-effects model, owing to
the lack of heterogeneity, indicates that a short-term, high-
dose statin pretreatment significantly reduces the incidence of
periprocedural myocardial infarction in patients undergoing
PCI when a universal, contemporary definition of such a
complication31 is used; in particular, use of high-dose statins
was associated with a 44% risk reduction for periprocedural
infarction, and 20 patients would need to be treated to avoid
1 event. High-dose statin pretreatment decreased the rate of
periprocedural myocardial infarction even when a per trial
definition was applied (60% risk reduction), and it decreased
the rate of periprocedural myocardial injury defined by any
troponin elevation (43% risk reduction). Occurrence of
periprocedural myocardial infarction by cardiac marker ele-
vation, even if clinically silent, may affect cardiovascular
outcome and overall survival in patients treated with PCI5; of
note, the relative increase in mortality at 6 months associated
with each elevation of CK-MB values has been demonstrated
Figure 2. Top, Odds ratios (with 95% confidence interval) of major adverse cardiac events at 30 days in patients receiving high-dose
statin pretreatment vs controls. Bottom, Funnel plot showing no evidence of publication bias. Abbreviations as in Figure 1.
Figure 3. Major adverse cardiac events curves at
30 days in high-dose statin vs control arms. PCI
indicates percutaneous coronary intervention.
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to be similar for both spontaneous and PCI-related myocar-
dial necrosis.38 Furthermore, previous studies demonstrated a
correlation between the degree of postprocedural CK-MB
increase and mortality risk during follow-up2–4; in particular,
a meta-analysis that pooled data from 23 230 patients5
showed that the excess mortality at 1 year was 1.7%, 2.8%,
and 7.4% for patients with postintervention CK-MB elevation
of 1 to 3 times ULN, 3 to 5 times ULN, and 5 times ULN,
respectively. Thus, therapeutic strategies able to reduce the
incidence of periprocedural myocardial injury may favorably
influence clinical outcome after PCI. Although there is
irrefutable evidence that periprocedural myocardial injury
results in higher mortality rates during long-term follow-up, a
meta-analysis assessing the long-term benefit of high-dose
statin pretreatment before PCI might add even more substan-
tial evidence for this particular treatment modality.
In the present meta-analysis, patients pretreated with high-
dose statins also had a 44% reduction in risk of 30-day
MACE after intervention (number needed to treat19).
Although the incidence of MACE may have been statistically
accounted for in part by periprocedural myocardial infarction,
other individual outcome measures, including spontaneous
myocardial infarction, 30-day mortality, and target-vessel
revascularization, were all considerably lower in the high-
dose statin arm, although these were not significant owing to
the small number of end points attained in these subgroup
analyses; future studies may well provide results for a larger
number of patients, thereby allowing a much more informa-
tive review of these potential benefits.
The incidence of MACE that did not include periproce-
dural myocardial infarction was lower in the high-dose statin
group (0.8% absolute reduction, 56% relative reduction),
which was of borderline significance because of the low
event rate but was similar to the overall finding for MACE
that included periprocedural myocardial infarction; impor-
tantly, this occurred despite the fact that all patients continued
statin treatment after intervention irrespective of initial ran-
domization assignment and that in the control arm, statin
therapy was initiated early after PCI. No evidence of publi-
cation bias was found in the results of the present meta-anal-
Figure 4. Incidence of periprocedural
myocardial infarction in the 2 groups
(high-dose statin pretreatment vs con-
trols) according to baseline high-
sensitivity C-reactive protein (CRP) lev-
els. RRR indicates relative risk reduction.
Figure 5. Periprocedural myocardial pro-
tection by high-dose statin across vari-
ous subgroups of patients. ACS indi-
cates acute coronary syndrome; PCI,
percutaneous coronary intervention; OR,
odds ratio; and CI, confidence interval.
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ysis, and no heterogeneity among the trials was found, despite
differences in the study designs. Moreover, when individual
data were pooled, subgroup analysis revealed that the clinical
benefit of high-dose statin pretreatment was significant irre-
spective of clinical presentation (48% reduction in risk of
periprocedural infarction in stable angina and 36% in ACS).
Because the absolute number of patients with ACS was
relatively low, a need remains for a large randomized,
controlled trial to focus on the relevant MACE and peripro-
cedural myocardial infarction reduction observed in the
present meta-analysis in this subset. Patients with severe renal
failure or with liver or muscle disease were excluded from all
trials by protocol, and this precluded assessment of a benefit
of high-dose statin in those subgroups of patients.
The possible mechanisms underlying the early protective
action of statins are unclear, but are not likely due to
cholesterol-lowering effects, because all trials included in the
analysis used a short-term pretreatment with high-dose statin
(median 0.5 days), which did not produce significant effects
on cholesterol levels. Various studies demonstrated early
lipid-independent (ie, pleiotropic) effects of statins, including
antithrombotic action,39 improvement of coronary flow ve-
locity reserve by vasodilation of coronary microvessels,40 and
rapid (12 hours after a single dose of atorvastatin) improve-
ment of endothelial function41; in particular, a planned
subanalysis of the ARMYDA trial42 showed that myocardial
protection conferred by atorvastatin is paralleled by attenua-
tion of procedural endothelial activation, with significant
reduction of adhesion molecules to peak levels after interven-
tion. Furthermore, in STATIN STEMI,23 pretreatment with
high-dose atorvastatin before primary PCI improved micro-
vascular coronary perfusion and ST-segment resolution rates
compared with low-dose atorvastatin. A higher inflammatory
status in patients undergoing PCI is associated with enhanced
risk of periprocedural complications and cardiac events dur-
ing follow-up.43,44 Statins have anti-inflammatory effects both
in vitro and in vivo.45,46 In the present meta-analysis, high-dose
statin pretreatment was associated with a lower post-PCI in-
crease in CRP levels and provided periprocedural cardioprotec-
tion mainly in the subgroup with elevated baseline CRP values;
because 4 studies did not perform measurement of CRP levels,
the study groups without CRP determination might have differed
in some way. The present meta-analysis provides additional
evidence to support the subclinical inflammatory hypothesis
of atherosclerosis and a likely mechanism by which high-
dose statins are beneficial as pretreatment for PCI. However,
patients with normal levels of high-sensitivity CRP have a
greatly reduced OR when treated with high-dose statins
compared with control subjects; this suggests that other
mechanisms may be at play that may ultimately influence
outcome during or after PCI. All of the aforementioned
pleiotropic effects of statins might contribute to decrease
myocardial necrosis due to procedural microembolization in
the setting of PCI. In particular, patients with ACS and high
inflammatory status, in whom there is a complex interaction
between endothelial dysfunction/activation, inflammation,
and thrombosis, may derive a relevant benefit from early
high-dose statin therapy before an invasive strategy.
Experimental data in mice have demonstrated that acute
administration of a statin can reduce infarct size after ligation
of the left anterior descending artery and subsequent reper-
fusion11,12,47; this animal model has enabled in-depth exper-
iments on the molecular mechanisms of this cardioprotection.
In particular, the beneficial effect of atorvastatin may share
the same molecular mechanisms as ischemic preconditioning,
ie, activation of nitric oxide synthase and promotion of
cyclooxygenase-2 and prostaglandin I2.47,48 Atorvastatin in-
duces rapid (within 5 minutes) activation of the phosphati-
dylinositol 3-kinase and serine/threonine kinase (Akt) signal-
ing cascades, which in turn causes phosphorylation and
activation of nitric oxide synthase.12 The beneficial effect of
atorvastatin on infarct size is absent in nitric oxide synthase
knockout mice and may be reversed by administration of
specific inhibitors of phosphatidylinositol 3-kinase or nitric
oxide synthase.12,47 Interestingly, the acute protective effect
of atorvastatin on myocardial injury in the animal model may
wane with a longer treatment, but this effect can be recap-
tured by a “reloading” given immediately before ischemia/
reperfusion.48 In the ARMYDA-RECAPTURE trial,20 short-
term pretreatment with a high-dose atorvastatin load before
PCI was associated with improved periprocedural outcome
even in patients undergoing chronic statin therapy, who
represent a relevant proportion of those patients receiving
percutaneous revascularization.
Although results of retrospective studies (which included
patients receiving a multitude of statins) may suggest the
presence of a class effect, the large majority of prospective
randomized trials demonstrating periprocedural cardioprotec-
tion by statins in patients undergoing PCI used a short-term
pretreatment with high doses of a potent statin (atorvastatin or
rosuvastatin). In particular, studies using atorvastatin 80 mg
and rosuvastatin 40 mg before PCI represented 54% and 19%,
respectively, of the overall weight in the present meta-anal-
ysis. Thus, when a strategy of short-term pretreatment with
statins before PCI is adopted, it would be appropriate to use
potent statins at high doses (ie, atorvastatin 80 mg or
rosuvastatin 40 mg).
Study Limitations
Of the trials identified, the sole investigators who declined to
participate in the patient-level analysis were Veselka et al,22
ie, the authors of 1 of the 2 studies in which a significant
clinical benefit by statin pretreatment was not demonstrated.
Although their data were entered in the trial-level analysis
and did not affect the overall results, lack of inclusion in the
patient-level analysis may represent a study limitation. An-
other limitation is that the included studies used different
dosing strategies of statins, and the time points at which
cardiac markers were measured after PCI were variable.
Moreover, 4 of the 13 studies22,24,26,28 did not collect 30-day
data, and the MACE for those 4 studies only included
periprocedural myocardial infarction. Finally, because the
antithrombotic treatments used in the various trials appear to
be different, the robustness of meta-driven conclusions may
be limited and the clinical benefit of high-dose statins
observed in the present meta-analysis may be affected; a
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standardized approach to antithrombotic therapies in a larger
randomized trial would help eliminate this confounder.
Conclusions
Cost-effectiveness analysis of the initiation of statin therapy
before PCI would likely be very favorable, because there was
no risk excess associated with high-dose loading with statins
before the procedure (none of the trials reported significant
side effects), and the cost of a few doses of statin is
negligible. The consistency across the trials and the strength
of the effect observed in the present meta-analysis suggest
that a strategy of high-dose statin pretreatment should be used
routinely in patients undergoing PCI, irrespective of clinical
presentation and chronic statin therapy; guideline committees
should consider updates to incorporate this novel strategy for
peri-PCI prevention of ischemic events.
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CLINICAL PERSPECTIVE
In this collaborative patient-level meta-analysis of 13 randomized, controlled trials (n3341 patients), we demonstrated
that short-term pretreatment with high-dose statins reduces the incidence of periprocedural myocardial infarction and early
major adverse cardiac events in patients undergoing percutaneous coronary intervention. This outcome improvement was
irrespective of clinical presentation, chronic statin therapy, or antithrombotic treatment, and was more pronounced in
patients with high baseline inflammatory status. Our results strengthen the concept that the clinical benefit provided in the
short-term by high-dose statins is due to pleiotropic effects. These data suggest that a strategy of early initiation of
high-dose statins should be implemented routinely in patients who are candidates for percutaneous coronary intervention,
and guideline committees should consider updates to incorporate this novel strategy for periprocedural percutaneous
coronary intervention prevention of ischemic events.
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